1 Economic burden of cancer across the European Union: a population-based cost analysis The Lancet Oncology, January 2, 2014
2 Clinical significance of RKIP mRNA expression in non-small cell lung cancer Tumor Biology, January 21, 2014
3 Cancer treatment disparities in HIV-infected individuals in the United States Journal of Clinical Oncology, July 22, 2014
4 Filaggrin loss-of-function mutations and incident cancer: A population-based study British Journal of Dermatology, March 21, 2014
5 The association of hospital spending intensity and cancer outcomes: A population-based study in an Asian country The Oncologist, August 20, 2014 Free full text
Question: True or False: The use of IV bisphosphonates for prevention of skeletal-related events (SREs) is higher in patients with bone metastases due to metastatic breast cancer than in patients with metastatic prostate cancer or metastatic lung cancer.
Question: Which bisphosphonate was the most efficacious in a mixed-treatment meta-analysis for reducing the risk of skeletal-related events (SREs) in patients with metastatic breast or prostate cancer?